Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Restructuring Costs: 2022-2025

Historic Restructuring Costs for BridgeBio Pharma (BBIO) over the last 4 years, with Sep 2025 value amounting to $8.8 million.

  • BridgeBio Pharma's Restructuring Costs rose 91.32% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 27.80%. This contributed to the annual value of $15.6 million for FY2024, which is 96.88% up from last year.
  • Per BridgeBio Pharma's latest filing, its Restructuring Costs stood at $8.8 million for Q3 2025, which was up 998.26% from $805,000 recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Restructuring Costs high stood at $22.7 million for Q1 2022, and its period low was $272,000 during Q3 2023.
  • Over the past 3 years, BridgeBio Pharma's median Restructuring Costs value was $3.4 million (recorded in 2023), while the average stood at $3.1 million.
  • Per our database at Business Quant, BridgeBio Pharma's Restructuring Costs crashed by 94.58% in 2023 and then surged by 1,598.90% in 2024.
  • Over the past 4 years, BridgeBio Pharma's Restructuring Costs (Quarterly) stood at $7.7 million in 2022, then tumbled by 90.20% to $754,000 in 2023, then spiked by 522.41% to $4.7 million in 2024, then soared by 91.32% to $8.8 million in 2025.
  • Its Restructuring Costs was $8.8 million in Q3 2025, compared to $805,000 in Q2 2025 and $570,000 in Q1 2025.